Study Year of publication Study
design 		Patients/
implants 		ADs Gender Follow-up
perioda 		Survival rate of implants Survival rate of
suprastructures 		Crestal
bone lossa 		PI Success rate
n/n M/F Months % (n/n patients)
% (n/n implants) 		% (n/n patients)
% (n/n suprastructures) 		mm % (n/n patients)
% (n/n implants) 		% (n/n patients)
% (n/n implants)
Oczakir et al. [6] 2005 CS 1/8 SSc+sSS 0/1 60 100% (1/1)
100% (8/8) 		100% (1/1)
100% (2/2) 		NR 0% (0/1)
0% (0/8) 		NR
Baptist [31] 2016 CR 1/6 SSc 0/1 24 100% (1/1)
100% (6/6) 		100% (1/1)
100% (2/2) 		Mean: 0.58 100% (1/1)
16.7% (1/6) 		NR
Bayram et al. [32] 2021 CR 1/7 SSc 0/1 57.6 100% (1/1)
100% (7/7) 		NR 0 0% (0/1)
0% (0/7) 		NR
Garces Villala et al. [42] 2021 CR 1/12 SSc 0/1 120 100% (1/1)
100% (12/12) 		100% (1/1)
100% (2/2) 		Mean: 1.22 0% (0/1)
0% (0/12) 		NR
Haas [44] 2002 CR 1/7 SSc 0/1 6 100% (1/1)
100% (7/7)c 		Irr. NR NR NR
Jensen et al. [47] 1990 CR 1/9 SSc 1/0 19 0% (0/1)
88.9% (8/9)
Early loss: 1
Late loss: 0 		100% (1/1)
100% (1/1) 		0 0% (0/1)
0% (0/8) 		NR
Langer et al. [48] 1992 CR 1/2 SSc 0/1 6 100% (1/1)
100% (2/2) 		NR NR NR NR
Nam et al. [55] 2012 CR 1/14 SSc+sSS 0/1 4 100% (1/1)
100% (14/14)c 		Irr. NR NR NR
Patel et al. [57] 1998 CR 1/4 SSc+FA 0/1 Up to prosthetic loading 100% (1/1)
100% (4/4)c 		NR NR NR NR
Raviv et al. [59] 1996 CR 1/3 SSc 0/1 24 100% (1/1)
100% (3/3) 		100% (1/1)
100% (1/1) 		NR NR NR
Smojver et al. [60] 2021 CR 1/4 SSc 0/1 12 100% (1/1)
100% (4/4) 		100% (1/1)
100% (2/2) 		NR NR NR
Zigdon et al. [62] 2011 CR 1/12 SSc 0/1 36 100% (1/1)
100% (12/12) 		NR 0 NR NR
Krennmair et al. [71] 2010 RS 1/4 SSc+RA+sSS 0/1 34 100% (1/1)
100% (4/4) 		100% (1/1)
100% (1/1) 		NR NR NR
Alenazi [84] 2021 CCS 7/NR SSc+RA NR Mean: 44.6b 100% (7/7)
NR 		100% (7/7)
NR 		NR NR NR
14/39 Control group 7/7 Mean: 39.4 100% (14/14)
100% (39/39) 		100% (14/14)
NR 		Median: 0.6 NR NR
Overall
SSc - CR: 11
CS: 1
CCS: 1
RS: 1 		20/92 - Ratio: 1/12 Mean: 33.6 95% (19/20)
98.9% (91/92)
Of these: 100% (1/1) early loss 		100% (14/14)
100% (11/11) 		Mean: 0.37 20% (1/5)
2.4% (1/41) 		NR
SSc+concomitant ADs - CR: 2
CS: 1
CCS: 1
RS: 1 		11/30 - Ratio: 0/4 Mean: 32.7 100% (11/11)
100% (30/30) 		100% (9/9)
100% (3/3) 		NR 0% (0/1)
0% (0/8) 		NR
Control group - CCS: 1 14/39 - Ratio: 1/1 Mean: 39.4 100% (14/14)
100% (39/39) 		100% (14/14)
NR 		Median: 0.6 NR NR

a = weighted mean or median; b = reported for RA+CTDs but NR specific for SSc; c = late loss NR.
ADs = autoimmune diseases; CCS = case-control study; CR = case report; CS = case series; CTDs = connective tissue diseases; FA = fibrosing alveolitis; Irr. = irrelevant; M/F = male/female; N = number; NR = not reported; PI = peri-implantitis; RA = rheumatoid arthritis; RS = retrospective study; sSS = secondary Sjögren's syndrome.